Metastatic Breast Cancer
Conditions
Keywords
Breast Cancer
Brief summary
In vitro data suggest synergy between oxaliplatin and 5-FU. The combination of oxaliplatin with 5-fluorouracil produced objective response rates ranging from 27-34% in two studies of patients with prior chemotherapy. Capecitabine was designed as an orally administered, tumor selective fluoropyrimidine, preferentially converted to 5-FU at the tumor site by the higher levels of pyrimidine nucleoside phosphorylase (PyNPase) in tumor tissues compared to normal tissues. The end result is higher concentrations of 5-fluorouracil in tumor relative to surrounding normal tissue. Trastuzumab is synergistic in vitro with multiple chemotherapeutic agents including the platinum compounds. Studies have shown the efficacy of trastuzumab combined with chemotherapy in patients with HER2 overexpressing metastatic breast cancer. This trial will investigate the activity of capecitabine and oxaliplatin administered with trastuzumab (CAPOX-T) in patients with HER2 overexpressing in patients with advanced disease.
Detailed description
OUTLINE: This is a multi-center study. * CAPOX-T (21 day cycle):Capecitabine 825 mg/m2 orally twice daily Days 1-14Oxaliplatin 100 mg/m2 intravenously Day 1 * Trastuzumab : 6 mg/kg intravenously Day 1.8mg/kg loading dose should be given in cycle 1 for patients without previous trastuzumab therapy only. Patients may continue combination therapy until progression or toxicity intervenes. Patients who discontinue either or both cytotoxic agents due to toxicity may, at the investigators discretion, continue therapy with the remaining agents on study until progressive disease ECOG performance status 0 or 1 Hematopoietic:· * ANC \> 1,200/mm3· * Platelets \> 100,000/mm3 Hepatic:· * Total bilirubin \< 1.5 x ULN· * AST \< 2 x ULN (up to 5 x ULN in patients with known liver involvement) Renal:· * Serum creatinine \< 1.5 x ULN and estimated creatinine clearance \>50ml/min as calculated with Cockroft-Gault equation Cardiovascular:· * No clinically significant cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication) or myocardial infarction within the last 12 months.· * LVEF \> LLN by MUGA or ECHO
Interventions
DRUGCapecitabine
Capecitabine 825 mg/m2 po bid, days 1-14
DRUGOxaliplatin
Oxaliplatin 100 mg/m2 IV, day 1
DRUGTrastuzumab
Trastuzumab 6mg/kg IV, day 1. 8 mg/kg loading dose given in cycle 1 for patients without previous trastuzumab therapy only.
Sponsors
Sanofi
Hoffmann-La Roche
Walther Cancer Institute
Hoosier Cancer Research Network
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologic or cytologic diagnosis of breast cancer with evidence of (1) unresectable, locally recurrent, or (2) metastatic disease.· * HER2 gene amplification by FISH. HER protein overexpression by immunohistochemistry will not be sufficient for entry.· * At least one measurable lesion as defined by the RECIST. * Prior hormonal therapy for metastatic disease is allowed. * Maximum of one prior chemotherapy regimen or trastuzumab-containing regimen for unresectable, locally recurrent or metastatic disease * Prior radiation therapy is allowed as long as the irradiated area is not the only source of measurable disease.
Exclusion criteria
* No prior therapy with capecitabine or oxaliplatin in any setting * No prior therapy with other platinum compounds· * No other forms of cancer therapy including radiation, chemotherapy and hormonal therapy within 21 days prior to beginning protocol therapy.· * No prior unanticipated severe reaction to fluoropyrimidine therapy, or known sensitivity to 5-fluorouracil.· * No prior fluoropyrimidine therapy for metastatic disease is allowed. * Prior adjuvant fluoropyrimidine therapy is allowed if completed \> 12 months from study entry.· * No symptomatic brain metastasis. · * No evidence of serious concomitant systemic disorders incompatible with the study · * No peripheral neuropathy · * No major surgery within 28 days prior to beginning protocol therapy.· * Negative pregnancy test· * No current breastfeeding· * No malabsorption syndrome· * No evidence of serious concomitant systemic disorders incompatible with the study· * Patients must not be treated with any of the following while on protocol therapy or within 28 days prior to beginning protocol therapy: sorivudine, brivudine, cimetidine, allopurinol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - · To determine the objective response rate (CR+PR) of capecitabine, oxaliplatin and trastuzumab(CAPOX-T) in patients with HER2 positive metastatic breast cancer. | 18 months |
Secondary
| Measure | Time frame |
|---|---|
| To determine toxicity rate of CAPOX-T in this patient population | 18 months |
| To measure time to progression | 18 months |
| To determine rate of clinical benefit response (CR + PR + SD > 6 months) | 18 months |
| To explore potential correlations between changes in HER2 circulating extracellular domain in the primary tumor with response | 18 months |
Countries
United States
Outcome results
None listed